AbbVie (ABBV) Announces FDA Approval for Addition of Moderate to Severe Fingernail Psoriasis Data to HUMIRA Prescribing Information
- S&P, Nasdaq enjoy boost from big tech firms, Dow ends a hair lower
- Zillow (ZG) Stock Falls on Report Company Paused Home Purchases due to High Demand, a Temporary Halt Yields a Chance for Competitors Says Analyst
- Oil prices pull back as U.S. factory data intensifies demand concerns
- Chip Shortages are Increasingly Becoming a New Bearish Risk, Inflation Bearish for Consumer Electronics - TFI's Kuo
- Walt Disney (DIS) Stock Slips as Barclays Downgrades Amid Disney+ Growth Slowdown
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the inclusion of moderate to severe fingernail psoriasis data in the HUMIRA® (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. HUMIRA is now the first-and-only biologic treatment with data on fingernail psoriasis in its U.S. prescribing information.
Fingernail psoriasis affects half of all psoriasis patients.1,2 It is a form of chronic plaque psoriasis characterized by pitting, deformation, thickening, discoloration, pain and separation of the nail from the nail bed.1,3 Nail psoriasis can also contribute to social stigmatization and impact quality of life. 2
"Fingernail psoriasis is often difficult to treat, and we are pleased the FDA recognized the importance of these data so that more healthcare providers can make informed medical decisions when prescribing treatments for those living with psoriasis," said John Medich, Ph.D., vice president, clinical development, Immunology, AbbVie. "AbbVie's nearly 20 years of research in immunology provides us with in-depth knowledge of challenging diseases and allows us to identify ways to address them - it is our hope that the fingernail psoriasis data will support healthcare providers treating this difficult condition."
The Phase 3 study was dedicated to evaluating fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis. The study demonstrated nearly half of adult patients treated with HUMIRA achieved an assessment of clear or minimal with at least a two-grade improvement from baseline in signs and symptoms of fingernail psoriasis compared to 6.9 percent of placebo patients (p<0.001). No new safety signals for HUMIRA were observed in the study.
In 2008, HUMIRA was FDA approved to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate. These fingernail psoriasis data are included as a third psoriasis study (Study Ps-III) in the plaque psoriasis clinical studies section (14.8) of the HUMIRA label and can be found here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CRL is a Negative, but Omeros (OMER) Stock is Trading Far Below Fundamental Value - Analyst
- Vermilion Energy (VET) Appoints James J. Kleckner Jr. to its Board
- Toll Brothers (TOL) Appoints Scott D. Stowell to its Board
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!